A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure

Anti-Cancer Drugs

Volumn 11, Issue 2, 2000, Pages 129-136

  Eksborg, Staffan ^a   Palm, Carina ^a   Björk, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

4' Epi doxorubicin; Anthracyclines; Children; Dosing; Doxorubicin; Leukemia; Pharmacokinetics

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE;

EID: 0034078137     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200002000-00010     Document Type: Article

References (50)

1. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200-8.
2. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
3. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
4. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
5. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21: 477-9.
6. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
7. Eksborg S. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 1990; 29: 339-42.
8. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 1916; 17: 863-71.
9. James WPT. Research on Obesity. London: HMSO 1976.
10. Eksborg S, Ehrsson H, Andersson I. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr 1979; 164: 479-86.
11. Saijo N. Chemotherapy: The more the better? Overview. Cancer Chemother Pharmacol 1997; 40 (suppl): S100-6.
12. Cosolo WC, Morgan DJ, Seeman E, Zimet AS, McKendrick JJ, Zalcberg JR. Lean body mass, body surface area and epirubicin kinetics. Anti-Cancer Drugs 1994; 5: 293-7.
13. Gunvén P, Theve NO, Peterson C. Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer. Cancer Chemother Pharmacol 1986; 17: 153-6.
14. Speth PA, Van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31.
15. Stallard S, Morrison JG, George WD, Kaye SB. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol 1990; 25: 286-90.
16. Preisler HD, Gessner T, Azarnia N, et al. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1984; 12: 125-30.
17. Hu OY, Chang SP, Jame JM, Chen KY. Pharmacokinetic and pharmacodynamic studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 1989; 24: 332-7.
18. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993; 45: 788-856.
19. Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 1994; 26: 428-38.
20. Eksborg S, Strandler HS, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985; 28: 205-12.
21. De Valeriola D. Dose optimization of anthracyclines. Anticancer Res 1994; 14: 2307-13.
22. Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994; 30A: 844-51.
23. Kummen M, Lie KK, Lie SO. A pharmacokinetic evaluation of free and DNA-complexed adriamycin: A preliminary study in children with malignant disease. Acta Pharmacol Toxicol 1978; 42: 212-8.
24. Evans WE, Crom WR, Yee GC, et al. Adriamycin pharmacokinetics in children. Proc Am Ass Cancer Res/Am Soc Clin Oncol 1980; 21: 176 (abstr 705).
25. Holcenberg JS, Kun LE, Ring BJ, Evans WE. Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. Int J Radiat Oncol Biol Phys 1981; 7: 953-6.
26. Crom WR, Reily CA, Green AA, Hayes FA, Pratt CB, Evans WE. Doxorubicin disposition in children and adolescents with cancer. Drug Intel Clin Pharm 1983; 17: 448 (abstr).
27. McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer 1992; 66 (suppl XVIII): S23-9.
28. Eksborg S, Hardell L, Bengtsson NO, Sjödin M, Elfsson B. Epirubicin as a single agent therapy for the treatment of breast cancer - A pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 1992; 9: 75-80.
29. Loebstein R, Koren G. The ethics of multiple blood sampling in children for research. Ther Drug Monit 1997; 19: 251.
30. Martini A, Moro E, Pacciarini MA, Tamassia V, Natale N, Piazza E. Cross-over study of pharmacokinetics and haematological toxicity of 4′-epi-doxorubicin and doxorubicin in cancer patients. Int J Clin Pharmacol Res 1984; 4: 231-8.
31. Eksborg S, Andersson M, Domellöf L, Lönroth U. A pharmacokinetic study of adriamycin and 4′-epi-adriamycin after simultaneous intra-arterial liver administration. Med Oncol Tumor Pharmacother 1986; 3: 105-10.
32. Eksborg S, Stendahl U, Lönroth U. Comparative pharmacokinetic study of adriamycin and 4′-epi-adriamycin after their simultaneous intravenous administration. Eur J Clin Pharmacol 1986; 30: 629-31.
33. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 1988; 21: 221-8.
34. Mross K, Maessen P, Van der Vijgh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517-26.
35. Reilly JJ, Workman P. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol 1994; 34: 3-13.
36. Zuccaro P, Guandalini S, Pacifici R, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 1991; 13: 37-41.
37. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet 1989; 17 (suppl 1): 68-88.
38. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-7.
39. LeBaron S, Zeltzer LK, LeBaron C, Scott SE, Zeltzer PM. Chemotherapy side effects in pediatric oncology patients: Drugs, age, and sex as risk factors. Med Pediatr Oncol 1988; 16: 263-8.
40. Lanning M, Garwicz S, Hertz H, et al. Superior treatment results in females with high-risk acute lymphoblastic leukemia in childhood. Acta Paediatr 1992; 81: 66-8.
41. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36: 473-6.
42. Paz-Ares L, Dobbs N, Twelves C. Doxorubicin-induced cardiotoxicity [letter; comment]. N Engl J Med 1995; 333: 1360.
43. Kohnoe S, Yoshida M, Takahashi I, Emi Y, Maehara Y, Sugimachi K. Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. Anticancer Res 1992; 12: 389-92.
44. Bontenbal M, Andersson M, Wildiers J, et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. Br J Cancer 1998; 77: 2257-63.
45. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 1987; 23: 1477-83.
46. Nair R, Ramakrishnan G, Nair NN, et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 1998; 82: 2282-8.
47. Ali-El-Dein B, El-Baz M, Aly AN, Shamaa S, Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): A randomized prospective study. J Urol 1997; 158: 68-73.
48. Tidefelt U, Sundman-Engberg B, Paul C. Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epi-doxorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 1989; 24: 225-9.
49. Okunewick JP, Kociban DL, Buffo MJ. Comparative hematopoietic toxicity of doxorubicin and 4′-epirubicin. Proc Soc Exp Biol Med 1990; 195: 95-9.
50. Meyer RM, Quirt IC, Skillings JR, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770-6.